JP2003524017A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003524017A5 JP2003524017A5 JP2001562565A JP2001562565A JP2003524017A5 JP 2003524017 A5 JP2003524017 A5 JP 2003524017A5 JP 2001562565 A JP2001562565 A JP 2001562565A JP 2001562565 A JP2001562565 A JP 2001562565A JP 2003524017 A5 JP2003524017 A5 JP 2003524017A5
- Authority
- JP
- Japan
- Prior art keywords
- bcmp
- breast cancer
- antibody
- subject
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 description 17
- 206010006187 Breast cancer Diseases 0.000 description 13
- 208000026310 Breast neoplasm Diseases 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 102100037086 Bone marrow stromal antigen 2 Human genes 0.000 description 4
- 101000740785 Homo sapiens Bone marrow stromal antigen 2 Proteins 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 229940124651 anti-breast cancer agent Drugs 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 108091008053 gene clusters Proteins 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0004576.5 | 2000-02-25 | ||
| GBGB0004576.5A GB0004576D0 (en) | 2000-02-25 | 2000-02-25 | Proteins |
| GB0031341.1 | 2000-12-21 | ||
| GB0031341A GB0031341D0 (en) | 2000-12-21 | 2000-12-21 | Protein |
| PCT/GB2001/000748 WO2001062784A2 (en) | 2000-02-25 | 2001-02-21 | Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003524017A JP2003524017A (ja) | 2003-08-12 |
| JP2003524017A5 true JP2003524017A5 (enExample) | 2008-01-31 |
Family
ID=26243736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001562565A Pending JP2003524017A (ja) | 2000-02-25 | 2001-02-21 | タンパク質 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20030130214A1 (enExample) |
| EP (2) | EP1259604A1 (enExample) |
| JP (1) | JP2003524017A (enExample) |
| KR (1) | KR100740761B1 (enExample) |
| CN (1) | CN100384875C (enExample) |
| AT (1) | ATE352311T1 (enExample) |
| AU (3) | AU2001233913A1 (enExample) |
| BR (1) | BR0108659A (enExample) |
| CA (1) | CA2399999A1 (enExample) |
| DE (1) | DE60126248T2 (enExample) |
| ES (1) | ES2279801T3 (enExample) |
| IL (1) | IL151448A0 (enExample) |
| NZ (1) | NZ520967A (enExample) |
| WO (2) | WO2001062914A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7054758B2 (en) | 2001-01-30 | 2006-05-30 | Sciona Limited | Computer-assisted means for assessing lifestyle risk factors |
| GB0125072D0 (en) * | 2001-10-18 | 2001-12-12 | Oxford Glycosciences Uk Ltd | Protein |
| WO2003075014A2 (en) * | 2002-03-06 | 2003-09-12 | Oxford Glycosciences (Uk) Ltd | Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11 |
| US20040033530A1 (en) * | 2002-04-08 | 2004-02-19 | Awrey Donald E. | High throughput purification, characterization and identification of recombinant proteins |
| GB0208331D0 (en) * | 2002-04-11 | 2002-05-22 | Oxford Glycosciences Uk Ltd | Proteins |
| FR2846426B1 (fr) * | 2002-10-28 | 2004-12-10 | Bio Merieux | Procede de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie |
| JP2006526382A (ja) * | 2002-12-06 | 2006-11-24 | シンガポール ジェネラル ホスピタル ピーティーイー リミテッド | 中枢神経系の損傷 |
| WO2005029083A1 (en) * | 2003-09-22 | 2005-03-31 | Green Peptide Co., Ltd. | Prognosis in cancer patients vaccinated with a cancer antigen peptide-associated agent |
| WO2005034994A1 (ja) | 2003-10-10 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | 固形腫瘍治療剤 |
| JP2007520217A (ja) * | 2004-01-27 | 2007-07-26 | コンピュゲン ユーエスエイ，インク． | 新規ヌクレオチドおよびアミノ酸配列、ならびにそれを用いた乳癌診断のためのアッセイおよび使用方法 |
| KR100763902B1 (ko) * | 2004-02-20 | 2007-10-05 | 삼성전자주식회사 | 유방암 특이적 단백질, 그를 코딩하는 유전자, 및 상기단백질 또는 유전자를 이용한 유방암의 진단 방법 |
| WO2008104803A2 (en) * | 2007-02-26 | 2008-09-04 | Oxford Genome Sciences (Uk) Limited | Proteins |
| KR101398079B1 (ko) * | 2011-10-10 | 2014-05-27 | 재단법인 의약바이오컨버젼스연구단 | 글리실-티알엔에이 합성효소 및 캐드헤린을 이용한 암 예방 또는 치료제의 스크리닝 방법 |
| CN104447975A (zh) * | 2014-11-18 | 2015-03-25 | 深圳市人口和计划生育科学研究所 | 一种提取人肿瘤细胞膜蛋白的方法 |
| WO2017011375A1 (en) * | 2015-07-10 | 2017-01-19 | University Of Iowa Reseaarch Foundation | Bst-2 as a therapeutic target and a predictive/prognostic bio-signature for breast cancer growth and metastasis |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002508652A (ja) * | 1996-08-23 | 2002-03-19 | ヒューマン ジノーム サイエンシーズ，インコーポレイテッド | 新規なヒト増殖因子 |
| DE19813839A1 (de) * | 1998-03-20 | 1999-09-23 | Metagen Gesellschaft Fuer Genomforschung Mbh | Menschliche Nukleinsäuresequenzen aus Brusttumorgewebe |
| NZ516381A (en) * | 1999-06-30 | 2004-03-26 | Corixa Corp | Lung tumor proteins in the therapy and diagnosis of lung cancer |
-
2001
- 2001-02-21 IL IL15144801A patent/IL151448A0/xx unknown
- 2001-02-21 JP JP2001562565A patent/JP2003524017A/ja active Pending
- 2001-02-21 DE DE60126248T patent/DE60126248T2/de not_active Expired - Fee Related
- 2001-02-21 AU AU2001233913A patent/AU2001233913A1/en not_active Abandoned
- 2001-02-21 EP EP01905949A patent/EP1259604A1/en not_active Withdrawn
- 2001-02-21 WO PCT/GB2001/000729 patent/WO2001062914A1/en not_active Ceased
- 2001-02-21 CA CA002399999A patent/CA2399999A1/en not_active Abandoned
- 2001-02-21 AU AU3392901A patent/AU3392901A/xx active Pending
- 2001-02-21 AT AT01905965T patent/ATE352311T1/de not_active IP Right Cessation
- 2001-02-21 CN CNB018084885A patent/CN100384875C/zh not_active Expired - Fee Related
- 2001-02-21 BR BR0108659-6A patent/BR0108659A/pt not_active IP Right Cessation
- 2001-02-21 NZ NZ520967A patent/NZ520967A/en unknown
- 2001-02-21 KR KR1020027011130A patent/KR100740761B1/ko not_active Expired - Fee Related
- 2001-02-21 ES ES01905965T patent/ES2279801T3/es not_active Expired - Lifetime
- 2001-02-21 EP EP01905965A patent/EP1257285B1/en not_active Expired - Lifetime
- 2001-02-21 WO PCT/GB2001/000748 patent/WO2001062784A2/en not_active Ceased
- 2001-02-21 AU AU2001233929A patent/AU2001233929C1/en not_active Ceased
- 2001-02-23 US US09/791,392 patent/US20030130214A1/en not_active Abandoned
-
2002
- 2002-08-23 US US10/227,616 patent/US20030099662A1/en not_active Abandoned
-
2006
- 2006-08-24 US US11/509,841 patent/US20070212368A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003524017A5 (enExample) | ||
| JP2006500949A5 (enExample) | ||
| JP2012526544A5 (enExample) | ||
| JP2007506426A5 (enExample) | ||
| KR20110020853A (ko) | 유전자 또는 단백질 발현 프로파일을 이용한 신장 동종이식 거부반응 진단방법 | |
| JP2016047044A (ja) | Ｂｃｌ−２ファミリー阻害剤耐性腫瘍及び癌を有する被験者を同定、分類及びモニターするための方法及び組成物 | |
| EP3152560B1 (en) | Non-invasive gene mutation detection in lung cancer patients | |
| EP3840634A1 (en) | Methods related to bronchial premalignant lesion severity and progression | |
| JP2009092508A (ja) | リウマチ治療剤の効果の予測方法 | |
| US12325880B2 (en) | Identification of PDE3 modulator responsive cancers | |
| WO2012121978A2 (en) | Biomarkers for the diagnosis of lacunar stroke | |
| JP2013178260A5 (enExample) | ||
| JP2008510168A (ja) | 骨関節炎のバイオマーカー | |
| CN111826466A (zh) | 乙型肝炎感染患者或携带者外泌体miRNA分子标志物组合及筛查试剂盒 | |
| JP2008512984A5 (enExample) | ||
| CN105102983B (zh) | Ddr2突变作为黑素瘤或基底细胞癌的可靶向的特征 | |
| CN112094896A (zh) | 活动性结核病诊断标志物、试剂盒及其应用 | |
| WO2010032177A1 (en) | Methods and compositions for diagnosing and treating a colorectal adenocarcinoma | |
| JP2013213774A (ja) | 結核検査用バイオマーカー | |
| JP2008547006A5 (enExample) | ||
| JP2006503575A5 (enExample) | ||
| RU2511394C2 (ru) | СПОСОБ И УСТРОЙСТВО ДЛЯ ПРЕДСКАЗАНИЯ ФАРМАКОЛОГИЧЕСКОЙ ЭФФЕКТИВНОСТИ ЛЕКАРТВЕННОГО СРЕДСТВА НА ОСНОВЕ ГУМАНИЗИРОВАННЫХ АНТИТЕЛ К ТNFα ДЛЯ ЛЕЧЕНИЯ РЕВМАТОИДНОГО АРТРИТА | |
| US20110151469A1 (en) | Interferon epsilon (ifne1) as a marker for targeted cancer therapy | |
| WO2017172521A1 (en) | Identification of unique blood-based gene expression profiles in children with regressive autism spectrum disorder (asd) and ileocolitis | |
| KR101789910B1 (ko) | 쇼그렌 증후군 진단 마커로서 ｓｉｇｌｅｃ５의 용도 |